Latest news
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 03 Aug 2026 11:22:18 GMTIMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand - BioPharma APACBioPharma APAC · Sun, 02 Aug 2026 18:34:30 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMTHow Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors - simplywall.stsimplywall.st · Thu, 30 Jul 2026 07:00:00 GMT